Actively Recruiting
A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital
Led by Lagos State Health Service Commission · Updated on 2025-12-30
138
Participants Needed
1
Research Sites
54 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to compare the short-term efficacy and safety of selective laser trabeculoplasty (SLT) to 0.005% latanoprost eye drops in lowering intraocular pressure (IOP) as primary therapy in treatment-naïve patients diagnosed as early to moderate primary open-angle glaucoma(POAG) or ocular hypertension (OHT) in the Lagos State University Teaching Hospital, Ikeja. The main questions it aims to answer are: 1. Will Selective Laser Trabeculoplasty be an equally effective treatment option compared with 0.005% Latanoprost eyedrops in reducing Intraocular Pressure when used alone as first-line therapy in Nigerian patients with POAG and OHT? 2. Will Selective Laser Trabeculoplasty record a similar safety profile compared with 0.005% Latanoprost when used independently as a primary therapy? 3. How will the quality of life of patients who undergo Selective Laser Trabeculoplasty treatment compare with patients on 0.005% Latanoprost eyedrops? Participants will be randomized to one of the two intervention groups. Group A(latanoprost group) will use 0.005% latanoprost eye drops every night at 2100hours(9.00pm) west African Time for 3 months. intraocular pressures will be monitored at intervals for a period of 3 months. Group B(SLT group) will have Laser treatment administered as a one-off treatment. intraocular pressures will be monitored at intervals for a period of 3 months. A record of side effects will be documented at each follow up visit
CONDITIONS
Official Title
A Comparative Study of Intraocular Pressure Control Using Selective Laser Trabeculoplasty and Latanoprost as Initial Treatments for Primary Open Angle Glaucoma and Ocular Hypertension in Lagos State University Teaching Hospital
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 18 years and above
- Newly diagnosed with primary open-angle glaucoma or ocular hypertension
- Elevated intraocular pressure greater than 21 mmHg based on three measurements taken on different visits
- Early or moderate glaucoma defined by specific eye exam criteria (cup-disc ratio 0.5 to 0.7, visual field MD -6 to -12 dB, DDLS 5 to 7)
- Agree to participate and provide informed consent
You will not qualify if you...
- Prior medical, surgical, or laser treatment for glaucoma
- Diagnosis of primary congenital or secondary glaucoma
- Advanced glaucoma (cup-disc ratio >0.8, visual field MD worse than -12 dB, DDLS stage 8 or higher)
- Cloudy cornea or corneal opacity impairing eye examination or pressure measurement
- Media opacity such as cataracts, vitreous haze, or hemorrhage preventing posterior eye exam
- Previous eye surgeries like cataract surgery or trabeculectomy
- History of eye trauma or uveitis
- Pregnant or lactating women
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Lagos State University teaching Hospital Eye Institute
Ikeja, Lagos, Nigeria
Actively Recruiting
Research Team
A
Anne I. Abang-Obi, MBBS
CONTACT
C
Chidinma C. Onyejekwe, FMCOph
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here